Regen BioPharma, Inc. (RGBP)
OTCMKTS · Delayed Price · Currency is USD
0.0210
-0.0048 (-18.60%)
Sep 11, 2025, 3:56 PM EDT
Regen BioPharma Revenue
Regen BioPharma had revenue of $59.07K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $236.56K, up 0.00% year-over-year. In the fiscal year ending September 30, 2024, Regen BioPharma had annual revenue of $236.56K.
Revenue (ttm)
236.56K
Revenue Growth
+0.00%
P/S Ratio
3.66
Revenue / Employee
236.56K
Employees
1
Market Cap
865.71K
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 236.56K | - | - |
Sep 30, 2023 | 236.56K | 1.04K | 0.44% |
Sep 30, 2022 | 235.52K | 64.32K | 37.57% |
Sep 30, 2021 | 171.19K | 61.19K | 55.63% |
Sep 30, 2020 | 110.00K | - | - |
Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
Regen BioPharma News
- 2 months ago - Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc. - Accesswire
- 10 months ago - Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™ - GlobeNewsWire
- 1 year ago - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 25, 2024, At 4 pm Eastern Time - GlobeNewsWire
- 1 year ago - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on May 9, 2024 - PRNewsWire
- 1 year ago - Regen BioPharma, Inc. to Discuss Plans to Move Forward with HemaXellerate into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024 - PRNewsWire
- 1 year ago - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on March 7, 2024 - PRNewsWire
- 1 year ago - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024 - PRNewsWire
- 1 year ago - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 10, 2024 - PRNewsWire